Citations

Clear

2438 citation(s) found for "Ly, Amy".

Errors on Cognitive Testing in Asymptomatic and Prodromal Familial Frontotemporal Dementia and their Prognostic Utility
Palacios, Brandon R., Casaletto, Kaitlin B. , Taylor, Jack C. , Wise, Amy B. , Dhanam, Sreya , Heuer, Hilary W. , Forsberg, Leah K. , Rosen, Howard J., Boxer, Adam L., Tempini, Maria Luisa Gorno , Kramer, Joel H. , Staffaroni, Adam M. , Sanderson‐Cimino, Mark , Paolillo, Emily W. , Bui, Minh , Boeve, Bradley F. , Boxer, Adam L. , Miller, Bruce L. , Seeley, William W.

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S4 | Pages: No page available

10.1002/alz.093114 Get It

AbstractBackgroundThe earliest cognitive manifestations of asymptomatic and prodromal familial frontotemporal dementia (f‐FTD) mutation carriers are still being characterized. Patients with symptomatic FTD are known to be error prone, particularly on tasks of executive function, but little is known about the frequency or predictive utility of these errors in the earliest stages of f‐FTD. The current study compared error rates on executive functioning tasks in controls and asymptomatic and prodromal mutation carriers and investigated whether errors predict worsening clinical status as follow up.MethodThis study included 90 participants (mean age = 48.57, SD = 13.30; 51.1% female; 86.67% white) with pathogenic FTD mutations (C9orf72, n = 45; GRN, n = 30; or MAPT, n = 15) who were asymptomatic or prodromal (Clinical Dementia Rating plus FTLD; CDR®+NACC‐FTLD ≤ 0.5). Propensity score matching identified (CDR®+NACC‐FTLD = 0) who did not carry pathogenic mutation but were matched on age, education, and sex. Regressions were used to compare controls and mutation carriers on error scores (rule violations and/or repetitions) from three executive functioning tasks: design fluency, lexical fluency, and Stroop inhibition. Mutation carriers with longitudinal data within 1.5 years were binarized as stable (n = 35) or progressors (n = 13) based on whether their CDR®+NACC‐FTLD sum of boxes score was worse at follow up (mean follow up = 1.07 years). Regressions were fit to evaluate the relationship between baseline error scores and group (i.e., stable vs. progressor).ResultMutation carriers committed significantly more errors than controls on the Stroop task (β = 0.67, p = 0.03) and lexical fluency (repetitions: β = 0.27, p = 0.02). The groups did not significantly differ in errors on the remaining tasks. A greater number of Stroop errors predicted mutation carriers who progressed at follow up (β = 1.04, p<0.001). When introducing the primary outcome from each task as a covariate (e.g., correct responses), the fluency task (repetitions: β = 0.10, p = 0.03) and Stroop task (errors: β = 0.82, p<0.001) were significantly associated with progression.ConclusionErrors on executive tasks may be early cognitive features in familial FTD. Importantly, errors were uniquely predictive above and beyond total scores. Research in larger samples will enable investigations of genetic differences in error rates.
Longitudinal self‐administered smartphone assessments capture cognitive decline and disease progression in presymptomatic and early symptomatic FTLD
Wise, Amy B. , Dhanam, Sreya, Taylor, Jack C. , Heuer, Hilary W. , Young, Jacob , Casaletto, Kaitlin B. , Palacios, Brandon R., Forsberg, Leah K. , Kornak, John , Weıntraub, Sandra , Rascovsky, Katya, Rankin, Katherine P. , Fields, Julie A. , Kramer, Joel H. , Rosen, Howard J. , Boxer, Adam L. , Staffaroni, Adam M. , Sanderson‐Cimino, Mark , Paolillo, Emily W. , Dhanam, Sreya , Hassenstab, Jason , Bui, Minh , Saloner, Rowan , Kremers, Walter K. , Wong, Bonnie , Boeve, Bradley F.

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S4 | Pages: No page available

10.1002/alz.090579 Get It

AbstractBackgroundMany treatments targeting frontotemporal lobar degeneration (FTLD) are in the developmental pipeline, but the rarity of the disease, coupled with the behavioral and motor features of FTLD, make it challenging to identify sufficient trial participants who can attend frequent in‐person visits. Decentralized clinical trial designs with remote evaluations are attractive alternatives but require validated tools for symptom tracking. Our previous cross‐sectional analyses showed that cognitive tasks deployed via the ALLFTD Mobile App are reliable and sensitive to early stages of disease. The current study seeks to evaluate whether unsupervised smartphone cognitive tests are sensitive to longitudinal changes that occur with increasing FTLD disease stage.MethodThe study included 194 participants (mean baseline age 54.30, SD = 15.66; mean education = 16.52, SD = 2.31; 55.2% women) who were asymptomatic (Clinical Dementia Rating plus FTLD (CDR®+NACC‐FTLD) = 0 [n = 109; 43 carriers of FTLD‐associated genetic variants]), prodromal (CDR®+NACC‐FTLD = 0.5 [n = 39]), or symptomatic (CDR®+NACC‐FTLD>0.5 [n = 46]) at baseline. Participants completed ALLFTD Mobile App smartphone versions of Stroop, flanker, and 2‐back tasks, as well as an adaptive associative memory task, every six months for up to two years. Linear‐mixed effects models investigated the effect of disease severity on cognitive trajectories by testing the interaction of baseline CDR®+NACC‐FTLD box score and time on smartphone test scores. Analyses were repeated in the subsample of asymptomatic/prodromal CDR®+NACC‐FTLD<1) familial FTLD mutation carriers (C9orf72, n = 27; MAPT, n = 16). All models controlled for age, education, and sex.ResultGreater baseline disease severity was associated with lower cognitive scores across all tasks (β range: ‐0.28 to ‐0.13; p’s < 0.001), and faster rates of decline on the memory and 2‐back tasks (β range: ‐0.15 to ‐0.07; p’s<0.04). When the sample was restricted to asymptomatic and prodromal individuals (CDR®+NACC FTLD<1), greater baseline disease severity was still associated with lower scores across most tasks (β range: ‐0.48 to ‐0.27; p’s<0.002; 2‐back: β = ‐0.19, p = 0.26). When the sample was restricted to asymptomatic/prodromal mutation carriers, disease severity remained associated with the memory and flanker tasks (β range: ‐0.85 to ‐0.45; p’s<0.01).ConclusionThis study provides initial evidence that longitudinal smartphone‐based cognitive measurements capture the accelerated cognitive worsening that accompanies increasing disease progression in FTLD.
Subjective cognitive concerns are associated with unsupervised smartphone‐based measures of memory and executive functioning in cognitively intact adults
Dhanam, Sreya , Young, Clayton, Taylor, Jack C. , Wise, Amy B. , Clark, Annie L , Heuer, Hilary W. , Kwang, Winnie, Kramer, Joel H. , Rosen, Howard J. , Weiner, Michael W. , Nosheny, Rachel L. , Staffaroni, Adam M. , Boxer, Adam L. , Bui, Minh , Sanderson‐Cimino, Mark , Paolillo, Emily W. , Boeve, Bradley F.

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S10 | Pages: No page available

10.1002/alz.094369 Get It

AbstractBackgroundSubjective cognitive concerns are common in functionally intact adults, potentially indicating future cognitive decline. Remote smartphone cognitive testing holds promise for objectively tracking cognition in individuals reporting complaints. In our initial exploration of the link between subjective cognitive complaints and digital clinical outcomes, we examined participants' self‐reported cognitive complaints' association with smartphone tests on memory and executive functioning.MethodsParticipants, without self‐reported MCI or dementia, were recruited from the UCSF Brain Healthy Registry (BHR) to complete cognitive tasks on their personal smartphone with the ALLFTD Mobile App. Participants also completed the 12‐item Everyday Cognition Screening Tool (ECog‐12), assessing subjective cognitive impairment, online as part of BHR. Average ECog‐12 scores, including Memory and Executive Functioning subdomains, were calculated. Correlations between scores from online ECog‐12 scores and app‐based smartphone tasks were examined. Regression analyses, adjusting for age, education, and sex, were performed to evaluate the relationship between ECog‐12 and smartphone tasks (Stroop & Flanker) measuring executive function and memory.ResultsOut of 2,283 invited BHR participants, 456 (mean age: 64.6 years (SD = 11.8) and education: 16.3 years (SD = 2.4)) completed smartphone tasks (81.1% completion rate). Age was negatively associated with executive functioning and memory tasks (ß’s = ‐0.51 to ‐0.54, p’s<0.05), while higher education correlated with better performance (ß’s = 0.10‐0.14, p’s<0.05). Sex was not significantly associated with performance on any task (ß’s = ‐0.04 to 0.09, p’s>0.05). Subjective cognitive concerns were linked to tasks of executive functioning (Stroop: ß = ‐0.18, p = 0.002) and memory (ß = ‐0.14, p = 0.02). Endorsement of executive functioning items on ECog‐12 associated with Stroop performance (ß = ‐0.16, p = 0.005), and memory‐specific complaints were related to memory performance (ß = ‐0.1, p = 0.09). The relationship with flanker scores was not significant (ß = ‐0.08, p = 0.17). Similar patterns emerged with the online ECog‐12; online and app‐based scores are strongly correlated (ß = 0.75, p<0.05).ConclusionsIn this cognitively intact sample, subjective cognitive concerns were linked to poorer performance on ALLFTD Mobile App tasks assessing executive functioning and memory. These findings suggest that unsupervised remote smartphone testing merits further consideration to monitor cognition in individuals with subjective cognitive concerns. Subsequent studies in deeply phenotyped cohorts with follow‐up assessments are essential for understanding the clinical relevance of these results.
Insights into laryngeal Castleman disease: A comprehensive scoping review with a case study focus
Weiss, Natalie , Bridges, Margaret, Rutt, Amy L. , Candelo, Estephanía , Rutt, Amy L. , Bridges, Margaret

Mayo Clinic

Laryngoscope Investigative Otolaryngology | January 7, 2025 | Volume: 10 | Issue: 1 | Pages: No page available

10.1002/lio2.70069 | PMID 39780857 Get It

AbstractIntroductionCastleman disease (CD) refers to a heterogeneous group of lymphoproliferative disorders, which rarely involves the larynx. Our goal in this study is to elucidate the clinical presentation, diagnostic techniques, and treatment methods of laryngeal CD through a scoping review and the addition of a new case.MethodsDue to limited existing literature, we employed a mixed methodology for review. First, we searched Google Scholar using terms related to laryngeal CD. Subsequently, we screened abstracts using Covidence, drawing from databases such as PubMed, Science Direct, ProQuest, and EMBASE. We shortlisted studies for data extraction, focusing on clinical presentations, diagnostics, and treatment methodologies. Finally, we described our additional case.ResultsScoping review revealed five qualifying laryngeal CD articles. Presenting symptoms included dysphagia, hoarseness, and dyspnea. Diagnosis was always established through histopathologic analysis. Management included local excision or radiotherapy. In our additional case, a 71‐year‐old male with known CD presented with neck swelling, dysphagia, and dysphonia. Exam revealed lymphoid laryngeal and supraglottic hyperplasia and edema. Laryngeal symptoms improved with medical management of CD.DiscussionGiven the rarity of laryngeal CD, its identification and management can be a challenge. Practitioners should be aware of characteristic points in a CD patient's history, physical exam, imaging, and biopsies. Local excision of obstructive lymphoid tissue and radiation are the best‐supported therapies. This study aims to build toward improvements in accurate diagnosis and appropriate treatment for laryngeal CD.
Updated Geriatrics Competencies for Graduating Medical Students: Training Physicians to Provide Age-Friendly Care
Schwartz, Andrea Wershof , Sehgal, Mandi , Dawson, Catherine M. P. , Granville, Lisa , Powers, Becky , Shah, Amit , Sullivan, Amy , Leipzig, Rosanne M. , Powers, Becky B , Shah, Amit A , Sullivan, Amy M , Schwartz, Andrea Wershof

Mayo Clinic

Academic Medicine | January 3, 2025 | Volume: 100 | Issue: 5 | Pages: 592-599

10.1097/acm.0000000000005958 | PMID 39752580 Get It

Abstract Purpose Medical student education in geriatrics is a critical need for every doctor-in-training as the population ages, with fewer than 7,000 geriatricians, and older patients, who now approach 20% of the U.S. population, having unique health care needs. This study presents the updated competencies in geriatrics for graduating medical students, framed by the Geriatrics 5Ms (Mind, Mobility, Medications, Multicomplexity, and What Matters Most). Method From 2019–2022, a working group of the American Geriatrics Society (AGS) drafted the updated medical student geriatrics education competencies, using a modified Delphi approach. The working group reviewed the literature, conducted an initial survey of working group members, and drafted and refined proposed updates to the competencies. The 27 resulting competencies were disseminated as a national survey to geriatrics experts and medical school education deans. Following the national survey, the competencies were updated and presented at the 2021 AGS Annual Scientific Meeting and open to public comment before they were finalized. Results The 27 updated geriatrics competencies for medical students included several new competencies, such as a focus on health equity, frailty, deprescribing, and patient priorities. A total of 211 respondents completed the national survey, including geriatrics experts (187/398, response rate: 47.0%) and education deans (24/191, response rate: 12.6%). All 27 proposed competencies met the predetermined threshold of 70% cumulative agreement, with a range of 93.0% (174/187) to 100% (187/187) among geriatrics experts and 87.5% (21/24) to 100% (24/24) among education deans. Conclusions The updated Geriatrics Competencies for Graduating Medical Students met with broad agreement among the geriatrics experts and medical school education deans who responded to the national survey. By focusing on the Geriatrics 5Ms, the competencies highlight key knowledge and skills graduating medical students need for the first day of internship to be prepared to deliver age-friendly care to older adults under their care.
A harmonized memory composite score for cross‐cohort Alzheimer’s disease and related dementia research: development and validation
Gross, Alden L. , Casaletto, Kaitlin B. , Chatterjee, Ankita , Albert, Marilyn S. , Apostolova, Liana G. , Boersema, Brooke, Boxer, Adam L., Clark, Lindsay R. , Eloyan, Ani , Farias, Sarah Tomaszewski , Hammers, Dustin B. , Wise, Amy B. , Yballa, Claire, Hampstead, Benjamin M. , Rascovsky, Katya, Ringman, John M. , Rosen, Howard J., Salmon, David P. , Kramer, Joel H. , Staffaroni, Adam M. , Sanderson‐Cimino, Mark , Gaynor, Leslie S. , Paolillo, Emily W. , Boxer, Adam L. , Boeve, Bradley F. , Joie, Renaud La , Gonzales, Mitzi M. , Hammers, Dustin B , Cobigo, Yann , Schonhaut, Daniel R. , Mechanic-Hamilton, Dawn J. , Miller, Bruce L. , Rabinovici, Gil D. , Ryman, Sephira G. , Smith, Glenn E. , DeCarli, Charles

Mayo Clinic

Alzheimer's & Dementia | January 3, 2025 | Volume: 20 | Issue: S3 | Pages: No page available

10.1002/alz.093383 Get It

AbstractBackgroundThe Uniform Data Set (UDS) neuropsychological battery, administered across Alzheimer’s Disease Centers (ADC), includes memory tests but lacks a list‐learning paradigm. ADCs often supplement the UDS with their own preferred list‐learning task. Given the importance of list‐learning for characterizing memory, we aimed to develop a harmonized memory score that incorporates UDS memory tests while allowing centers to contribute differing list‐learning tasks.MethodWe applied item‐banking confirmatory factor analysis to develop a composite memory score in 5,287 participants (mean age 67.1; SD = 12.2) recruited through 18 ADCs and four consortia (DiverseVCID, MarkVCID, ALLFTD, LEADS) who completed UDS memory tasks (used as linking‐items) and one of five list‐learning tasks. All analyses used linear regression. We tested whether memory scores were affected by which list‐learning task was administered. To assess construct validity, we tested associations of memory scores with demographics, disease severity (CDR Box Score), an independent memory task (TabCAT Favorites, n = 675), and hippocampal volume (n = 811). We compared performances between cognitively unimpaired (n = 279), AD‐biomarker+ MCI (n = 26), and AD‐biomarker+ dementia (n = 98). In a subsample with amyloid‐ and tau‐PET (n = 49), we compared memory scores from participants with positive vs negative scans determined using established quantitative cutoffs.ResultModel fit indices were excellent (e.g., CFI = 0.998) and factor loadings were strong (0.43‐0.93). Differences in list‐learning task had a negligible effect on scores (average Cohen’s d = 0.11). Higher memory scores were significantly (p’s<.001) correlated with younger age (β = ‐0.18), lower CDR Box Scores (β = ‐0.63), female sex (β = 0.12), higher education (β = 0.19), larger hippocampal volume (β = 0.42), and an independent memory task (β = 0.71, p<0.001). The memory composite declined in a stepwise fashion by diagnosis (cognitively unimpaired>MCI>AD dementia, p<0.001). On average, amyloid‐PET positivity was associated with lower composite scores, but was not statistically significant (β = ‐0.34; p = 0.25; d = 0.40). Tau‐PET positivity was associated with worse performance, demonstrating a large effect size (β = ‐0.75; p<0.002; d = 0.91).ConclusionThe harmonized memory score developed in a large national sample was stable regardless of contributing list‐learning task and its validity for cross‐cohort ADRD research is supported by expected associations with demographics, clinical measures, and Alzheimer’s biomarkers. A processing script will be made available to enhance cross‐cohort ADRD research.
Passively collected data from smartphones improves detection of frontotemporal dementia compared to the MoCA
Casaletto, Kaitlin B. , Taylor, Jack C. , Heuer, Hilary W. , Wise, Amy B. , Dhanam, Sreya, Palacios, Brandon R., Young, Jacob , Dutt, Shubir , Cadwallader, Claire J. , Kramer, Joel H. , Forsberg, Leah K. , Rosen, Howard J. , Boxer, Adam L. , Staffaroni, Adam M. , Paolillo, Emily W. , Dhanam, Sreya , Sanderson‐Cimino, Mark , Bui, Minh , Saloner, Rowan , VandeBunte, Anna M. , Kremers, Walter K. , Boeve, Bradley F.

Mayo Clinic

Alzheimer's & Dementia | January 3, 2025 | Volume: 20 | Issue: S3 | Pages: No page available

10.1002/alz.090571 Get It

AbstractBackgroundFrontotemporal dementia (FTD) is a common young‐onset dementia. Challenges to in‐person FTD evaluations (e.g., behavioral symptoms, disease rarity), highlight the need to develop remote, low‐burden assessment techniques. A growing literature supports passive digital phenotyping for monitoring neurobehavioral change. Thus, we examined the utility of passively collected data from smartphones to detect prodromal or symptomatic FTD compared to that of the Montreal Cognitive Assessment (MoCA), a common cognitive screener.Method199 adults enrolled in the ALLFTD Mobile App study (mean age = 53.4 [SD = 15.2]; 58% women) completed up to 6 months of passive smartphone monitoring via the ALLFTD Mobile App. 55% were unimpaired [CDR®+NACC FTLD = 0], 22% had prodromal FTD [CDR®+NACC FTLD = 0.5], and 23% had symptomatic FTD [CDR®+NACC FTLD≥1] with a variety of syndromic presentations. Battery percentage was collected frequently (median interval = 45 min), and total daily battery usage was calculated as a proxy for smartphone use (higher battery usage = more smartphone use). Daily step counts were also passively collected. Logistic regression classified prodromal or symptomatic FTD vs. unimpaired as a function of: MoCA score [Model 1]; 7 passive features characterizing average, inter‐day variability, and changes over time in smartphone use and movement [Model 2]; or passive smartphone features and MoCA [Model 3]. Analyses were repeated excluding participants with symptomatic FTD to detect prodromal FTD vs. unimpaired.ResultThe area under the curves (AUCs) for detecting prodromal or symptomatic FTD (vs. unimpaired) from the MoCA alone [Model 1] and passive smartphone features alone [Model 2] were 0.77 (95%CI: 0.70‐0.85) and 0.77 (95%CI: 0.70‐0.84), respectively. Their combination [Model 3] resulted in a significantly improved AUC of 0.86 (95%CI: 0.80‐0.92) compared to Model 1 (p = 0.001). Significant Model 3 predictors included average daily battery usage (p = 0.02), slopes of change in step count (p = 0.04), and MoCA score (p<0.01). When distinguishing prodromal FTD from unimpaired, passive smartphone features alone (AUC = 0.75) were significantly better than the MoCA alone (AUC = 0.66; p<0.01), and their combination had the largest AUC (0.80).ConclusionResults support the utility of novel passively collected information from smartphones for detecting and monitoring FTD without contributing to assessment burden. With continued validation, passive digital monitoring methodologies have potential to increase access to dementia care.
Physicians-in-training and advanced practice providers perceptions in managing perioperative obstructive sleep apnea: a multi-institutional survey
Lyons, M. Melanie , Auckley, Dennis , Charchaflieh, Jean , Myers, John V., Yılmaz, Meltem , Williams, Lisa , Khan, Meena , Card, Elizabeth , Gelfand, Brian J., Pilla, Michael A., Loftsgard, Theodore O. , Sawyer, Amy M. , Matura, Lea Ann , Carlucci, Melissa , Sahni, Ashima , Glaser, Kathleen, Ghussain, Dana E. Al, Bhatt, Nitin, Rosen, Ilene M. , Gali, Bhargavi , Mokhlesi, Babak , Ghussain, Dana Al, Brock, Guy , Magalang, Ulysses J

Mayo Clinic

Journal of Clinical Sleep Medicine | December 31, 2024 | Volume: 21 | Issue: 5 | Pages: 765-773

10.5664/jcsm.11528 | PMID 39745490 Get It

Advancing drug development in myelodysplastic syndromes
McGraw, Kathy L. , Cunningham, Lea, Kim, Nina , Jen, Emily Y. , Ehrlich, Lori A. , Aplan, Peter D. , Garcia‐Manero, Guillermo , Foran, James M. , Zeidan, Amer M., Scott, Bart L. , Buckstein, Rena , Tinsley-Vance, Sara, Verma, Amit , Wroblewski, Tanya, Pavletic, Steven Z. , Zeidan, Amer M. , Verma, Amit , Kim, Nina , Jen, Emily Y , Ehrlich, Lori A , Aplan, Peter D , Garcia, Jacqueline S , Komrokji, Rami S , Sekeres, Mikkael A , Scott, Bart , Verma, Amit , Zeidan, Amer M , Mina, Alain , Calvo, Katherine R. , Garcia, Jacqueline S. , Dezern, Amy Elizabeth , Komrokji, Rami S. , Sekeres, Mikkael A. , Norsworthy, Kelly J.

Mayo Clinic

Blood Advances | December 30, 2024 | Volume: 9 | Issue: 5 | Pages: 1095-1104

10.1182/bloodadvances.2024014865 | PMID 39786387 Get It

Abstract Myelodysplastic syndromes/neoplasms (MDSs) are heterogeneous stem cell malignancies characterized by poor prognosis and no curative therapies outside of allogeneic hematopoietic stem cell transplantation. Despite some recent approvals by the US Food and Drug Administration, (eg, luspatercept, ivosidenib, decitabine/cedazuridine, and imetelstat), there has been little progress in the development of truly transformative therapies for the treatment of patients with MDS. Challenges to advancing drug development in MDS are multifold but may be grouped into specific categories, including criteria for risk stratification and eligibility, response definitions, time-to-event end points, transfusion end points, functional assessments, and biomarker development. Strategies to address these challenges and optimize future clinical trial design for patients with MDS are presented here.